Arcutis Completes Enrollment in INTEGUMENT-1 Pivotal Phase III Trial of Roflumilast Cream in Atopic Dermatitis

Arcutis Biotherapeutics, Inc. announced the enrollment of the last subject in its INTEGUMENT-1 pivotal Phase III trial of roflumilast cream 0.15% in adults and children with atopic dermatitis.
[Arcutis Biotherapeutics, Inc.]
Press Release

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News